Chinese English Japanese Germany Korea

Canagliflozin heMihydrate

Canagliflozin heMihydrate 구조식 이미지
카스 번호:
Canagliflozin heMihydrate
Cageline;TA7284 hemihydrate;TA-7284 hemihydrate;Invokana hemihydrate;Canagliflozin hydrate;Cagliflozin heMihydrate;JNJ28431754 hemihydrate;JNJ 28431754 hemihydrate;JNJ-28431754 hemihydrate;Canagliflozin heMihydrate
포뮬러 무게:
MOL 파일:

Canagliflozin heMihydrate 속성


Canagliflozin heMihydrate C화학적 특성, 용도, 생산


Canagliflozin, an orally active and selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, was co-developed by Mitsubishi Tanabe Pharma and Johnson & Johnson (J&J) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The drug was approved in March by the U.S. FDA and launched in April 2013 in the U.S. SGLT2 is involved in the glucose re-absorption pathway in the kidney, and its inhibition increases urinary glucose excretion, and reduces plasma glucose and HbA1c levels. In addition, canagliflozin is safe in combination with other commonly used antidiabetic agents and has a significant effect on body weight reduction. A recently published process patent from ScinoPharm Taiwan describes the synthesis of canagliflozin.


Canagliflozin Hemihydrate is a derivative of Canagliflozin (C175190), which is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.

Chemical Synthesis

Synthesis of the aglycone region of canagliflozin was described in a separate patent by first condensing commercially available 5- bromo-2-methylbenzoyl chloride (14) and 2-(4-fluorophenyl)- thiophene (15) under Friedel–Crafts acylation conditions to give ketone 16 in 69% yield as a crystalline solid. Ketone 16 was then reduced with triethylsilyl hydride in the presence of BF3Et2O at low temperature to give aglycone bromide 17 in 70% yield. The precursor for the glycoside moiety, commercially available glycoside triol 18, was selectively treated with t-butyldiphenylsilyl chloride (TBDPSCl) in THF in the presence of imidazole to give the bis-silyl ether 19 in 81% yield. Next, a unique, stereospecific b-C-arylglucosidation was developed to secure the union of the aglyone- and glycoside-containing portions of canagliflozin. Bromide 17 was subjected to magnesium powder under standard Grignard conditions prior to treatment with AlCl3 in THF in situ. This resulting mixture was then exposed to a solution of compound 19 in PhOMe which had been pre-treated with n-BuLi, and the entire mixture was then warmed to 150 ℃ for 5 h to ultimately give the b-anomer 20 in 56% yield. Finally, removal of the silyl groups within 20 with tetrabutyl ammonium fluoride (TBAF) in THF delivered canagliflozin hydrate (III) in 73% yield.

Canagliflozin heMihydrate 준비 용품 및 원자재


준비 용품

Canagliflozin heMihydrate 공급 업체

글로벌( 183)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Shanghai Rochi Pharmaceutical Co.,Ltd.
15000076078 0086-21-38751876 CHINA 432 58
Anqing Chico Pharmaceutical Co., Ltd.
15380796838 CHINA 341 58
Henan DaKen Chemical CO.,LTD.
+86-371-66670886 China 15418 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 China 22607 55
Hangzhou FandaChem Co.,Ltd.
+86-571-56059825 China 9165 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070 CHINA 3013 60
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 739 60
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 26781 60
career henan chemical co
+86-0371-55982848 China 29953 58
Shanghai Arbor Chemical Co., Ltd.
021-60451683 CHINA 906 58

Copyright 2019 © ChemicalBook. All rights reserved